The combination of a 25% dilutive share issuance to a known distressed lender (Streeterville) and an active ATM program signals ongoing cash burn and limited financing options. The shares are immediately tradable, so monitor for accelerated selling by Streeterville. The remaining ATM capacity of ~$9.8 million adds further overhang.
Price Chart
Executive Summary
Jaguar Health entered into exchange agreements with Streeterville Capital to issue 481,584 shares of common stock in exchange for a $3.4 million reduction in the outstanding balance of a secured promissory note from 2021. The shares were issued without restrictive legends under Section 3(a)(9) of the Securities Act, and the company disclosed approximately 1,945,542 shares outstanding as of September 25, 2026. This debt-for-equity swap reduces leverage but adds immediate dilution of ~25% to the share count, and the shares are immediately tradable, creating near-term selling pressure.
Key Financial Metrics
Key Facts
- Issued 481,584 shares to Streeterville Capital in exchange for $3.4 million reduction in the 2021 Note balance.
- Shares issued under Section 3(a)(9) exemption — no restrictive legend, immediately tradable via DWAC.
- Dilution of ~24.7% based on 1,945,542 shares outstanding as of September 25, 2026.
- The 2021 Note originally had a principal amount of $6,220,812.50; remaining balance after this exchange is undisclosed.
- Cross-filing: 424B5 filed 4 days prior (September 24, 2026) disclosed an ATM capacity of up to $9.8 million, with ~$4.9 million already sold in the prior 12 months.
- Stock closed at $8.91 on September 23, 2026, per the 424B5 supplement.
Financial Impact
Dilution of ~24.7% from 481,584 new shares; $3.4 million debt reduction; ATM program still has ~$9.8 million capacity remaining.
Risk Factors
- Streeterville may sell the 481,584 shares immediately, creating downward price pressure.
- Remaining ATM capacity of ~$9.8 million could be drawn down, further diluting existing holders.
- The company's cash position and burn rate are not disclosed in this filing, but the need for debt-for-equity swaps and ATM sales suggests ongoing capital constraints.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-403356 |
| Document: d187815dex101.htm | 0001193125-26-403356 |
| Document: 0001193125-26-403356-index-headers.html | 0001193125-26-403356 |
| Document: 0001193125-26-403356-index.html | 0001193125-26-403356 |
| Document: 0001193125-26-403356.txt | 0001193125-26-403356 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | S-3 | $2.04 | awaiting T+60 | — | $2.24 (−9.80%) |
Oct 8, 2026 19d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.24 (+53.24%) |
Oct 5, 2026 22d ago | 8-K | $4.73 | awaiting T+60 | — | $2.24 (+52.64%) |
Sep 28, 2026 29d ago | 8-K | $6.02 | awaiting T+60 | — | $2.24 (+62.79%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.24 (+70.91%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.24 (+68.27%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.24 (+68.27%) |
Sep 21, 2026 5w ago | 8-K | $34.46 | awaiting T+60 | — | $2.24 (−93.50%) |
Sep 15, 2026 6w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.24 (−897.33%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.24 (+78.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers